Keyword: Department of Health and Human Services (HHS)
A company set up to provide safe, cheap prefilled syringes to developing countries is turning its expertise loose on the U.S.
For the second time this month, Gilead has suffered a setback in its public patent dispute with the U.S. government.
Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R&D.
Gilead and HHS are locked in a public fight over HIV prevention drug patents, and Gilead has lost the first round.
As the Trump administration works on its International Pricing Index proposal, pharma and conservative groups are on edge about a potential release.
In a rare move, HHS will allow Novartis to pay for travel and other out-of-pocket expenses for Medicare and Medicaid patients on CAR-T drug Kymriah.
Merck, Eli Lilly and Amgen will face the HHS in appeals court Monday, looking to extend their trial court win against drug prices in TV ads.
Gilead and HHS are starting a program to provide HIV prevention meds to uninsured people who can benefit for free.
The next courtroom showdown in the battle over drug prices in TV ads is set for Jan. 13 with Merck, Eli Lilly, Amgen and ANA versus HHS.
Gilead Sciences balked at licensing the U.S. government's HIV-prevention patent rights, and now the feds are striking back.